Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “IMIPRAMINE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,549 records · Page 86Linked to original sources
PubMed1989

A double-blind study of fluoxetine and imipramine in major depression.

Eighteen outpatients with major depression (diagnosis was made according to DSM-III criteria) were treated in a 5-week double-blind parallel group comparison of the new antidepressant fluoxetine with imipramine. From these results it can be shown that the drugs were comparable in efficacy, although because of the small sample size a moderate clinical difference between treatments may not have been detected. Imipramine and fluoxetine have already been compared in other studies, but never at such a low dosage (20 mg) for fluoxetine. At this dosage the fluoxetine safety profile seems to be very different from previous scheduled studies with higher dosages. In fact clinical efficacy seems to remain comparable while side-effects are significantly less frequent.

Depressive Disorder↗
PubMed1987

Alterations of beta-adrenergic, muscarinic cholinergic receptors and imipramine binding sites in human lung tumors.

Direct ligand binding techniques have been used to compare beta-adrenergic receptors, muscarinic cholinergic receptors and imipramine binding sites in human tumoral and healthy lungs removed from eleven patients during operations. Beta-adrenergic and muscarinic cholinergic receptors are present in tumoral tissues but their concentrations were decreased compared to healthy tissues. Imipramine binding sites were absent. It is concluded that this type of studies could bring additional information to morbid anatomy analysis and be used to follow illness evolution.

Adenocarcinoma↗
PubMed1985

Demonstration of an imipramine endacoid in rat brain.

The partial purification and characterization of an imipramine endacoid from rat brain is reported. High affinity 3H-imipramine binding as well as 3H-serotonin uptake in both brain and platelet preparations is inhibited in a dose-dependent fashion by the endogenous substance. The effect of the endogenous factor appears to be specific since it does not affect the binding of other drugs to their membrane receptors. The substance is resistant to proteolytic enzymes and is unevenly distributed in rat brain being highly concentrated in the hypothalamus and striatum. Its concentration in rat brain is not changed after repeated electroconvulsive shock treatment.

Animals↗
PubMed1986

[Interaction of piracetam with 3H-imipramine binding sites and the GAMA-benzodiazepine receptor complex of brain membranes].

Piracetam at a concentration of 10(-6) M was shown to behave as a noncompetitive inhibitor of 3H-imipramine specific binding to rat brain membranes. At the same time piracetam failed to influence specific binding of 3H-mianserin to membranes of guinea-pig cerebellum, which is indicative of its inability to suppress histamine H1 receptors, a component of 3H-imipramine specific binding sites. At a concentration of 10(-4) M piracetam does not change specific binding of 3H-flunitrazepam to rat hippocampal membranes in the absence of GABA, but in the presence of 5 X 10(-5) M GABA, like atypical tranquilizer mebicar, acts as a competitor of 3H-flunitrasepam binding. Though Ro-15 1788 did not suppress anxyolytic piracetam (and mebicar) effect, our results give evidence of a possible involvement of GABA-benzodiazepine supramolecular complex in the anxiolytic activity of piracetam.

Animals↗
PubMedDate not supplied

[Binding of tritiated imipramine to human platelets. 1 or several binding sites?].

Using Langers' method (10) under their laboratory conditions, the authors determined the characteristics of the high-affinity imipramine-binding site on human platelets in thirty-five normal subjects, equally divided between the sexes and distributed by decade from twenty to sixty years of age and above. Bmax was 440 +/- 121 fmol./mg. protein, Kd 0.96 +/- 0.62, 10(-9) M. Protein concentration was held within a range of 0.2 to 0.55 mg./ml. in order to avoid nonlinear bias with Bmax, expressed in fmol./ml. of incubate. The characteristics of the site did not co-vary with sex or age in this experimental series. However, subject to additional investigation, the curve of the Scatchard graph would seem to indicate the possible existence of a distinct, low-affinity imipramine-binding site.

Adult↗
PubMed1987

Imipramine receptors in human platelets: effect of age.

Imipramine receptors were studied in platelets from six healthy young subjects (age between 24 and 38 years), five newborns, and six healthy elderly persons (age between 70 and 81 years). Binding parameters, the maximum binding capacity (Bmax) and the apparent dissociation constant (Kd), were determined by Scatchard's analysis. Level of differences between young subjects and the other groups was determined by Student's t-test. Bmax (mean +/- SD) was 1162 +/- 138 (young persons), 564 +/- 65 (newborn), and 508 +/- 98 (elderly persons) fmol/mg protein. The figure for the young was different from that of the newborn (p less than 0.001) and the elderly (p less than 0.01). Kd (means +/- SD) was 1.78 +/- .69 (young persons), 0.68 +/- 0.13 (newborn), and 0.80 +/- 0.27 nM in the elderly. Kd in the volunteers was different from that in the newborn or the elderly subjects (p less than 0.01). Imipramine receptors in platelets appear to be influenced by development and aging.

Adult↗
PubMed1988

Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms.

Some researchers have recently suggested that antidepressants may be superior to benzodiazepines in the alleviation of generalized anxiety. In a 6-week, double-blind, parallel-design study with flexible dosage scheduling, the authors compared the effects of alprazolam with those of imipramine in 60 patients who had generalized anxiety disorder. On rating scales that contained both psychic and somatic symptoms, patients in both treatment groups improved to a similar degree after 2 weeks. However, alprazolam was more effective in attenuating somatic symptoms, and imipramine was more effective in attenuating psychic symptoms such as dysphoria and negative anticipatory thinking. The authors' results suggest that, in generalized anxiety, somatic symptoms and hyperarousal selectively respond to drugs acting on the gamma-aminobutyric acid system, whereas psychic symptoms respond to treatments affecting the noradrenergic or serotonergic systems.

Adult↗
PubMed1988

Clinical outcome and adverse effect profile associated with concurrent administration of alprazolam and imipramine.

Clinical outcome and adverse effects associated with concurrent alprazolam and imipramine administration were studied in 29 patients with major depressive disorder who completed a 6-week trial in which they served as their own controls. Alprazolam was added on Day 8 in gradually escalating, then gradually tapering dosages while imipramine dosages remained unchanged. Significant decreases were observed in scores on the Hamilton Rating Scales for Depression and Anxiety at all later evaluation days with Day 8 as baseline. The mean total Symptom and Side Effects score decreased significantly from Day 8 to Day 22 when alprazolam doses were 1 mg q.i.d. For most side effects, total number of reports remained constant or decreased from Day 1 to later evaluation days. Standing diastolic blood pressures were significantly lower on Day 22 than on Day 1. No significant relationship was found between any rating scale score and plasma concentration data.

Adult↗
PubMed1988

[Development of subsensitivity to imipramine in the system of reverse serotonin uptake by thrombocytes in patients with endogenous depression].

The inhibitory effect of imipramine (IC50) on [3H]serotonin uptake and its kinetic parameter (V400) were measured in platelets of 9 patients with unipolar and 6 with bipolar affective disorder. The IC50 and V400 values in depressed patients were significantly higher (p less than 0.002) than these found in the control group. Treatment with antidepressants significantly decreased the IC50 values. The results support the hypothesis postulating that depression is related to a decreased modulatory capacity of imipramine binding sites and that the clinical effectiveness of these drugs is associated with the said modulatory capacity.

Adolescent↗
PubMed1987

Minaprine and imipramine in the treatment of major depressive disorders. A comparative double-blind study.

Minaprine dihydrochloride is an aminopyridazine derivative which is chemically unrelated to other known psychotropic drugs. In rodents minaprine is active in most models of depression and is thought to exert this activity by enhancing serotonergic and dopaminergic transmission. In humans minaprine has been shown to be more effective than placebo in the treatment of major depressive episodes as defined by the DSM-III. In the present study, the efficacy and safety of minaprine (100 mg b.i.d.) in the treatment of major depressive disorders (DSM-III) were compared with those of imipramine (50 b.i.d.) in 104 patients, in a 4-week randomized, double-blind, multicentre trial. The two drugs were comparable in efficacy as judged by the Hamilton Depression Rating Scale, a Clinical Global impression and a Zung Self-Rating Scale. The onset of activity appeared to be significantly more rapid with minaprine. The incidence and intensity of unwanted effects was significantly higher in the imipramine treatment group.

Adult↗
PubMed1988

Imipramine treatment of panic disorder in a boy with Tourette's syndrome.

Tourette's syndrome patients may suffer associated behavior and emotional problems that require treatment intervention even when tic symptoms are mild. A case is reported of a boy with Tourette's syndrome whose panic attacks were successfully treated with imipramine. The results suggest that trials of imipramine might prove beneficial for Tourette's syndrome patients who experience panic attacks.

Age Factors↗
PubMedDate not supplied

Hepatic metabolism of imipramine after prolonged administration of the drug to rats. An in vivo study.

The effect of prolonged administration of imipramine (IMI) to rats on the biliary excretion of IMI and its metabolites desipramine (DMI), 2-OH-imipramine (2-OH-IMI) and 2-OH-desipramine (2-OH-DMI) has been investigated. It was found that chronic IMI decreased the ratio DMI/IMI and 2-OH-IMI/IMI excreted with the bile and increased the ratio 2-OH-DMI/DMI. This was observed for 3 h after the last dose of chronic IMI, and suggested an inhibition of IMI demethylation and hydroxylation, and acceleration of DMI hydroxylation. 6 h after the dose of IMI the biliary ratio DMI/IMI and 2-OH-IMI/IMI increased and this might indicate an acceleration of IMI metabolism at later time intervals after IMI administration.

Animals↗
PubMed1987

Comparison of alprazolam and imipramine for treatment of outpatient depression.

A 6-week double-blind comparison of the therapeutic efficacy of alprazolam and imipramine in 90 depressed psychiatric outpatients revealed a significantly superior response to alprazolam in the first 2 weeks of treatment as measured by total scores on the Hamilton Rating Scale for Depression and the Brief Psychiatric Rating Scale. Further analyses revealed that all significant differences could be accounted for by the superior effect of alprazolam on sleep disturbance. By the end of Weeks 4 and 6, no significant differences in therapeutic response between the two treatment groups were noted, with patients in both groups evidencing improvement on all measures. A differentially high dropout rate among patients in the imipramine treatment group posed a problem for interpretation of results in the latter weeks of treatment.

Adolescent↗
PubMed1987

Imipramine blood levels and clinical outcome.

Fifty-one depressed inpatients, after 1 drug-free week, were treated for 5 weeks with imipramine 4 mg/kg day. Plasma levels of imipramine (IMI) and its active metabolite desmethylimipramine (DMI) were measured weekly, 15 hours after the last drug intake. Steady state blood levels (IMI + DMI) ranged from 60 to 585 ng/ml. The mean value for plasma concentration (IMI + DMI) at day 42 was 271 ng/ml. In the same way, therapeutic effectiveness was assessed every week using the Hamilton Rating Scale for Depression (HDRS). There was a significant correlation between plasma concentration and the decrease of Hamilton scores. The IMI/DMI ratio showed a responder-nonresponder difference; 86% patients with a ratio between 0.4 and 1 were responders. Conversely, most patients with a ratio below 0.4 or above 1 were nonresponders. The ideal ratio for clinical response would be 0.68. The ratio is a subject-specific feature, able to be an early predictor of clinical outcome.

Adult↗
PubMedDate not supplied

[A double-blind comparison between mianserin and imipramine (author's transl)].

Fifty-four depressed patients aged 18 to 65 years were treated for 4 weeks with a daily dose of either 60 mg mianserin or 150 mg imipramine in a double-blind controlled trial. The results which were measured on the Hamilton rating scale, on the Beck and on the Overall rating scale, on the brief psychiatric rating scale (BPRS) and on a global rating scale, did not show any significant difference relative to the antidepressive efficiency of both products. The frequency of side-effects however was significantly lower in the mianserin group than in the imipramine group.

Adolescent↗
PubMed1985

A double-blind placebo-controlled study of fluvoxamine and imipramine in depression.

Outpatients with major affective disorder, unipolar depressed type (N=101), were treated in a 4-week placebo-controlled double-blind study to compare the efficacy and safety of fluvoxamine, a new serotonin reuptake inhibitor antidepressant, with imipramine and placebo. Therapy was initiated at 50 mg/day; thereafter, dosage ranged between 100 and 300 mg/day for both drugs. Results indicate statistically significant efficacy, measured by both patient and physician rating scales, for both active drugs over placebo. Fluvoxamine showed some evidence of earlier onset of action. Anticholinergic side effects were more common in the imipramine-treated patients, while fluvoxamine produced more gastrointestinal distress and insomnia.

Adult↗
PubMedDate not supplied

Changes in conditioned performance and general behavior produced by imipramine treatment in dogs.

Dogs with electrolytic damage of dorsomedial amygdala and lateral hypothalamus manifested the syndrome of depression. They were used as models for studying the effects of a tricyclic antidepressant. Imipramine treatment produced increase in general arousal, motility and reactivity as tested by various tests, changes in social behavior and only slight improvement of instrumental conditioned performance. In normal dogs the imipramine administration in most subjects resulted in either no effect or deterioration of various learned tasks. Strong individual differences in the reactivity to drug treatment were observed in both normal and lesioned (depressed) dogs.

Amygdala↗
PubMed1979

Depression treated with imipramine and ECT: the DeCarolis study reconsidered.

The authors reevaluate a large prospective Italian study (437 patients) that compared high-dose imipramine with ECT treatment in the treatment of depression. The superiority of ECT was evident among patients with endogenous depression, and especially evident among those with delusional depression (83% improved with ECT versus 40% with imipramine) and depressions defined as severe (83% versus 35%).

Adjustment Disorders↗